$CTOR News

Citius Oncology shares are trading higher. The company issued a commercial update on the U.S. launch of LYMPHIR for the treatment of cutaneous T-cell lymphoma.

Citius Oncology shares are trading higher. The company issued a commercial update on the U.S. launch of LYMPHIR for the treatment of cutaneous T-cell lymphoma.

Earnings Breakdown: Citius Oncology Q1

Citius Oncology Q1 Earnings Summary & Key Takeaways

Citius Oncology Q1 EPS $(0.06) Misses $(0.04) Estimate, Sales $3.944M Miss $4.373M Estimate

Citius Oncology Enters Distribution Agreement With Uniphar For LYMPHIR Distribution Into European Union

CORRECTION: Citius Oncology Is The Subsidiary Of Citius Pharmaceuticals

Citius Oncology Q4 EPS $(0.06), Inline

Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules

Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules

Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim

Citius Oncology Enters Exclusive Distribution Agreement With Er-Kim For Exclusive LYMPHIR Distribution Across Turkey And Key Gulf Cooperation Council Countries; Agreement Expands Citius Oncology's International Strategy To A Total Of 19 Markets Outside The U.S.

Citius Oncology Announces U.S. Commercial Launch of LYMPHIR™, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL)

Citius Oncology shares are trading higher after the company announced the commercial launch of LYMPHIR, FDA-Approved IL-2 receptor-directed fusion protein, for the treatment of adult patients with r/r Stage I–III cutaneous T-cell lymphoma after at least one prior systemic therapy.

Citius Oncology to Exhibit at the 67th American Society of Hematology (ASH) Annual Meeting

Citius Oncology to Advance Commercial Launch of LYMPHIR™ with Verix AI Integration

When Will Citius Oncology, Inc. (NASDAQ:CTOR) Become Profitable?

Citius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 Conferences

Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR™

Citius Oncology Establishes International Access to LYMPHIR™ via Named Patient Programs in Southern Europe